Addex Therapeutics (ADXN) Operating Margin (2019 - 2025)
Addex Therapeutics' (ADXN) quarterly Operating Margin came in at 314218.95% in Q4 2025, down 13152664.0% year-over-year from N/an in Q4 2024, and down 13315.94% quarter-over-quarter from 2342.13% in Q3 2025.
Powered by 
Analysis
Addex Therapeutics (ADXN) Operating Margin (2019 - 2025) Analysis & Trends
Addex Therapeutics has disclosed Operating Margin across 7 years of filings, most recently posting 314218.95% for Q4 2025.
- In Q4 2025, Operating Margin fell 13152664.0% year-over-year to 314218.95%; the TTM figure through Dec 2025 stood at 8688.09% (down 743266.0% YoY), while the FY2025 annual figure was 9390.76%, down 870894.0% from the prior year.
- Operating Margin came in at 314218.95% for Q4 2025 at Addex Therapeutics, down from 2342.13% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 62.8% in Q2 2023 to a low of 314218.95% in Q4 2025.
- Average Operating Margin over 5 years is 28665.27%, with a median of 898.96% recorded in 2022.
- Year-over-year, Operating Margin jumped 1089379 bps in 2021 and plunged 18123060 bps in 2024.
- Over 5 years, Operating Margin stood at 491.79% in 2021, then tumbled by 604 bps to 3463.7% in 2022, then surged by 58 bps to 1461.7% in 2023, then plunged by 12399 bps to 182692.31% in 2024, then sank by 72 bps to 314218.95% in 2025.
- Per Business Quant data, the three most recent Operating Margin figures were 314218.95% in Q4 2025, 2342.13% in Q3 2025, and 182692.31% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 42.23% |
| 10 | Addex Therapeutics | 3.27 Mn | 3.27 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -314,218.95% |
| Sep 30, 2025 | -2,342.13% |
| Dec 31, 2024 | -182,692.31% |
| Sep 30, 2024 | -1,155.71% |
| Jun 30, 2024 | -780.13% |
| Mar 31, 2024 | -337.50% |
| Dec 31, 2023 | -1,461.70% |
| Sep 30, 2023 | -228.61% |
| Jun 30, 2023 | -62.80% |
| Mar 31, 2023 | -73.47% |
| Dec 31, 2022 | -3,463.70% |
| Sep 30, 2022 | -1,017.78% |
| Jun 30, 2022 | -3,868.04% |
| Mar 31, 2022 | -2,429.04% |
| Dec 31, 2021 | -491.79% |
| Sep 30, 2021 | -524.31% |
| Jun 30, 2021 | -454.03% |
| Mar 31, 2021 | -372.89% |
| Dec 31, 2020 | -315.62% |
| Sep 30, 2020 | -11,418.10% |